SI4009978T1 - Uporaba sepiapterina in njegovih metabolitov za zdravljenje izpostavljenosti sevanju - Google Patents
Uporaba sepiapterina in njegovih metabolitov za zdravljenje izpostavljenosti sevanjuInfo
- Publication number
- SI4009978T1 SI4009978T1 SI202030521T SI202030521T SI4009978T1 SI 4009978 T1 SI4009978 T1 SI 4009978T1 SI 202030521 T SI202030521 T SI 202030521T SI 202030521 T SI202030521 T SI 202030521T SI 4009978 T1 SI4009978 T1 SI 4009978T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sepiapterin
- metabolites
- radiation exposure
- treat radiation
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882937P | 2019-08-05 | 2019-08-05 | |
| EP20758407.9A EP4009978B1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4009978T1 true SI4009978T1 (sl) | 2025-03-31 |
Family
ID=72148243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202030521T SI4009978T1 (sl) | 2019-08-05 | 2020-08-05 | Uporaba sepiapterina in njegovih metabolitov za zdravljenje izpostavljenosti sevanju |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220273661A1 (https=) |
| EP (2) | EP4454712A3 (https=) |
| JP (2) | JP7642611B2 (https=) |
| CN (2) | CN114555090B (https=) |
| AU (1) | AU2020324435B2 (https=) |
| BR (1) | BR112022002029A2 (https=) |
| CA (1) | CA3146477A1 (https=) |
| DK (1) | DK4009978T3 (https=) |
| ES (1) | ES2994060T3 (https=) |
| FI (1) | FI4009978T3 (https=) |
| HR (1) | HRP20241653T1 (https=) |
| HU (1) | HUE069012T2 (https=) |
| IL (1) | IL290321B1 (https=) |
| LT (1) | LT4009978T (https=) |
| MX (1) | MX2022001535A (https=) |
| PL (1) | PL4009978T3 (https=) |
| PT (1) | PT4009978T (https=) |
| RS (1) | RS66096B1 (https=) |
| SI (1) | SI4009978T1 (https=) |
| SM (1) | SMT202500089T1 (https=) |
| WO (1) | WO2021026247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| WO2005048926A2 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
| MX379061B (es) | 2013-09-13 | 2025-03-04 | Bioventures Llc | Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion. |
| CN106794197A (zh) | 2014-10-02 | 2017-05-31 | 西托索尔本茨公司 | 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途 |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-04 IL IL290321A patent/IL290321B1/en unknown
- 2020-08-05 AU AU2020324435A patent/AU2020324435B2/en active Active
- 2020-08-05 CN CN202080069308.5A patent/CN114555090B/zh active Active
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 LT LTEPPCT/US2020/045026T patent/LT4009978T/lt unknown
- 2020-08-05 DK DK20758407.9T patent/DK4009978T3/da active
- 2020-08-05 PL PL20758407.9T patent/PL4009978T3/pl unknown
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 SM SM20250089T patent/SMT202500089T1/it unknown
- 2020-08-05 JP JP2022507561A patent/JP7642611B2/ja active Active
- 2020-08-05 CN CN202411691224.1A patent/CN119837879A/zh active Pending
- 2020-08-05 HR HRP20241653TT patent/HRP20241653T1/hr unknown
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en not_active Ceased
- 2020-08-05 RS RS20241189A patent/RS66096B1/sr unknown
- 2020-08-05 EP EP24187395.9A patent/EP4454712A3/en active Pending
- 2020-08-05 SI SI202030521T patent/SI4009978T1/sl unknown
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 EP EP20758407.9A patent/EP4009978B1/en active Active
- 2020-08-05 PT PT207584079T patent/PT4009978T/pt unknown
- 2020-08-05 HU HUE20758407A patent/HUE069012T2/hu unknown
- 2020-08-05 FI FIEP20758407.9T patent/FI4009978T3/fi active
- 2020-08-05 ES ES20758407T patent/ES2994060T3/es active Active
-
2025
- 2025-02-26 JP JP2025029508A patent/JP2025098011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555090A (zh) | 2022-05-27 |
| US20220273661A1 (en) | 2022-09-01 |
| EP4454712A3 (en) | 2025-01-01 |
| FI4009978T3 (fi) | 2024-11-01 |
| JP2025098011A (ja) | 2025-07-01 |
| EP4009978A1 (en) | 2022-06-15 |
| HUE069012T2 (hu) | 2025-02-28 |
| EP4009978B1 (en) | 2024-09-25 |
| ES2994060T3 (en) | 2025-01-16 |
| CN119837879A (zh) | 2025-04-18 |
| BR112022002029A2 (pt) | 2022-06-07 |
| CA3146477A1 (en) | 2021-02-11 |
| RS66096B1 (sr) | 2024-11-29 |
| AU2020324435A1 (en) | 2022-02-24 |
| JP2022543655A (ja) | 2022-10-13 |
| IL290321B1 (en) | 2026-04-01 |
| LT4009978T (lt) | 2024-11-25 |
| HRP20241653T1 (hr) | 2025-04-25 |
| PL4009978T3 (pl) | 2025-02-24 |
| PT4009978T (pt) | 2024-11-05 |
| WO2021026247A1 (en) | 2021-02-11 |
| IL290321A (en) | 2022-04-01 |
| CN114555090B (zh) | 2024-12-17 |
| JP7642611B2 (ja) | 2025-03-10 |
| MX2022001535A (es) | 2022-03-04 |
| AU2020324435B2 (en) | 2026-03-19 |
| DK4009978T3 (da) | 2024-10-14 |
| SMT202500089T1 (it) | 2025-03-12 |
| EP4454712A2 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4009978T3 (pl) | Stosowanie sepiapteryny i jej metabolitów w leczeniu narażenia na promieniowanie | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL278978A (en) | Preparations and methods for treating eczema | |
| IL280000A (en) | Formulations for reducing tumors and methods of using them | |
| EP3692973A4 (en) | BACK SUPPORT FOR ANKLE SPHAT, AND ANKLE SPHAT | |
| EP3749700B8 (de) | Mit aktinischer strahlung fixierbare masse und ihre verwendung | |
| GB2589398B (en) | Compounds and methods of use | |
| SG11202011454TA (en) | Ex-vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds | |
| IL283061A (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| IL272847A (en) | Methods of using dantrolene to treat exposure to nerve gas | |
| SG11202009795PA (en) | Protection of biologically active molecules during radiation sterilization | |
| ZA202100752B (en) | Treatment and prevention of injury due to radiation exposure | |
| HK40060691A (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| ZA202104656B (en) | Deuterated forms and derivatives of volinanserin | |
| IL282566A (en) | Synthesis of (S)-6-hydroxytryptophan and their derivatives | |
| IL278575B1 (en) | Dantrolene formulations and methods of using them | |
| GB201908573D0 (en) | Compounds and methods of use | |
| IL283912B (en) | Methods for treating cancer using the platenoside molecule and its isomers | |
| IL277988A (en) | Compounds and methods for treating demyelination | |
| HK40051014A (en) | Methods and compositions for treating chronic effects of radiation and chemical exposure | |
| HK40042340A (en) | Using power loss density and related measures to quantify the dose of tumor treating fields (ttfields) | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions | |
| GB201809005D0 (en) | Compositions and methods realting to the treatment of psoriasis |